Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes.

CONTEXT Human leukocyte antigen (HLA) DQ haplotypes have the strongest genetic association with type 1 diabetes (T1DM) risk. OBJECTIVE The objective of the study was to analyze whether HLA DQ alleles influence the development of antiislet autoantibodies, the progression to T1DM among autoantibody-positive relatives, or both. DESIGN The Diabetes Prevention Trial-1 screened more than 90,000 nondiabetic relatives of patients for cytoplasmic islet-cell autoantibody (ICA) expression between 1994 and 2002. SETTING The study was conducted in the general community. PARTICIPANTS The Diabetes Prevention Trial-1 found 2817 ICA-positive relatives who were tested for biochemical autoantibodies (GAD65, ICA512, and insulin) and HLA-DQ haplotypes, and 2796 of them were followed up for progression to diabetes for up to 8 yr (median, 3.6 yr). MAIN OUTCOME MEASURE Progression to T1DM was measured. RESULTS High-risk DQ haplotypes and genotypes were associated with a higher percentage of relatives expressing multiple biochemical autoantibodies and higher T1DM risk (e.g., respectively, 59 and 36% at 5 yr for carriers of the DQA1*0301-DQB1*0302/DQA1*0501-DQB1*0201 genotype). The number of autoantibodies expressed significantly increased T1DM risk and across different DQ genotypes, autoantibody positivity directly correlated with diabetes risk. However, multivariate analyses indicated that the influence of most genotypes on T1DM risk was not independent from autoantibody expression, with the possible exception of DQA1*0102-DQB1*0602. Specific genotypic combinations conferred 5-yr diabetes risks significantly lower (e.g. 7%-DQA1*0201-DQB1*0201/DQA1*0501-DQB1*0201 and 14%-DQA1*0301-DQB1*0301/DQA1*0501-DQB1*0201) than when those haplotypes were found in other combinations. CONCLUSION HLA DQ alleles determine autoantibody expression, which is correlated with diabetes progression. Among autoantibody-positive relatives, most HLA DQ genotypes did not further influence T1DM risk.

[1]  Heather J Cordell,et al.  Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. , 2004, The Journal of clinical endocrinology and metabolism.

[2]  J. Krischer,et al.  High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial—Type 1 Diabetes , 2004, Diabetologia.

[3]  J. Ilonen,et al.  HLA DR-DQ-encoded genetic determinants of childhood-onset type 1 diabetes in Finland: an analysis of 622 nuclear families. , 2003, Tissue antigens.

[4]  J. Ilonen,et al.  Genetic modification of risk assessment based on staging of preclinical type 1 diabetes in siblings of affected children. , 2003, The Journal of clinical endocrinology and metabolism.

[5]  J. Krischer,et al.  Diabetes Prevention Trial 1 , 2002, Annals of the New York Academy of Sciences.

[6]  C. Greenbaum,et al.  ICA+ relatives with DQA1*0102/DQB1*0602 have expected 0602 sequence and DR types. , 2002, Journal of autoimmunity.

[7]  J. Todd,et al.  A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins. , 2001, Human molecular genetics.

[8]  J. Krischer,et al.  Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the Diabetes Prevention Trial-Type 1. , 2001, Diabetes.

[9]  E. Thorsby,et al.  DR- and DQ-associated protection from type 1A diabetes: comparison of DRB1*1401 and DQA1*0102-DQB1*0602*. , 2000, The Journal of clinical endocrinology and metabolism.

[10]  G. Eisenbarth,et al.  Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1. , 2000, The Journal of clinical endocrinology and metabolism.

[11]  M. Rewers,et al.  Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Erlich,et al.  Sequence analysis of the diabetes-protective human leukocyte antigen-DQB1*0602 allele in unaffected, islet cell antibody-positive first degree relatives and in rare patients with type 1 diabetes. , 1999, The Journal of clinical endocrinology and metabolism.

[13]  M. Rewers,et al.  Antiislet autoantibodies usually develop sequentially rather than simultaneously. , 1996, The Journal of clinical endocrinology and metabolism.

[14]  G. Eisenbarth,et al.  Limited loss of tolerance to islet autoantigens in ICA+ first degree relatives of patients with type I diabetes expressing the HLA dqb1*0602 allele. , 1996, Journal of autoimmunity.

[15]  H. Erlich,et al.  HLA-DQB1*0602 Is Associated With Dominant Protection From Diabetes Even Among Islet Cell Antibody–Positive First-Degree Relatives of Patients with IDDM , 1995, Diabetes.

[16]  J. Todd,et al.  A genome-wide search for human type 1 diabetes susceptibility genes , 1994, Nature.

[17]  J. Krischer,et al.  Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives. , 1994, The Journal of clinical investigation.

[18]  J. Todd,et al.  Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Todd,et al.  HLA-DQβ gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus , 1987, Nature.